跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

SML2868

Sigma-Aldrich

Aclidinium bromide

≥98% (HPLC)

别名:

(3R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, (3R)-3-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C26H30BrNO4S2
CAS号:
320345-99-1
分子量:
564.55
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D -24 to -30°, c = 0.1 in methanol

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

[s]1c(ccc1)C(O)(c5[s]ccc5)C(=O)O[C@@H]2C3CC[N+](C2)(CC3)CCCOc4ccccc4.[Br-]

InChI

1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1

InChI key

XLAKJQPTOJHYDR-QTQXQZBYSA-M

生化/生理作用

Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) bronchodilator. It is a muscarinic M3, M2 antagonist with a long residence time at M3 receptors and a shorter residence time at M2 receptors. Aclidinium bromide was approved for the treatment of chronic obstructive pulmonary disease (COPD) in July 2012.
Long-acting muscarinic receptor antagonist; Bronchodilator.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000109356
0000109357
0000106348

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Amadeu Gavaldà et al.
The Journal of pharmacology and experimental therapeutics, 331(2), 740-751 (2009-08-28)
Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M(1)-M(5)). [(3)H]Aclidinium dissociated slightly faster from M(2) and M(3) receptors
François Maltais et al.
Therapeutic advances in respiratory disease, 6(6), 345-361 (2012-10-19)
Long-acting muscarinic antagonists (LAMAs) play a central role in the management of chronic obstructive pulmonary disease (COPD). Previously, only one LAMA (tiotropium) was available for the treatment of COPD, necessitating the development of other therapeutic options due to the heterogeneity
Z-Z Li et al.
European review for medical and pharmacological sciences, 23(1), 105-112 (2019-01-19)
Osteosarcoma is recognized as the most common primary malignant bone tumor, the 5-year disease-free survival rate in patients with metastatic or recurrent disease is below than 30%. Drug resistance and toxic side effects limit the therapeutic efficacy of osteosarcoma. Therefore

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门